09:27 AM EST, 11/14/2025 (MT Newswires) -- Tempus AI ( TEM ) said Friday it is commencing a new follicular lymphoma research study in partnership with the Institute for Follicular Lymphoma Innovation.

The multi-year study will enroll participants to generate a multi-omic dataset to support research regarding precision medicine and biomarker discovery in follicular lymphoma, the company said.

Tempus' stock was down 4.7% in recent Friday premarket activity.